Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 16/20 | 0.72 |
| ▸ | FPR2 | P25090 | 4/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25723627 | 0.90 | CHRM5 (0.69) | CHRM5FPR2PROKR1 | |
| SCHEMBL25280604 | 0.88 | CHRM5 (0.66) | CHRM5FPR2PROKR1CYP3A4CYP2D6 | |
| SCHEMBL25723652 | 0.88 | CHRM5 (0.70) | CHRM5FPR2PROKR1CYP3A4CYP2D6 | |
| SCHEMBL25233149 | 0.84 | CHRM5 (1.00) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30457099 | 0.83 | CHRM5 (0.65) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25231202 | 0.83 | CHRM5 (0.70) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25275827 | 0.83 | CHRM5 (0.82) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25229853 | 0.80 | CHRM5 (0.82) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25232871 | 0.79 | CHRM5 (0.73) | CHRM5FPR2PROKR1CYP3A4CYP2D6 | |
| SCHEMBL25233755 | 0.78 | CHRM5 (0.82) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | CHRM5 1/4885FPR2 3822/4885PROKR1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.